Dimiracetam: Phase IIa data

Top-line data from an 8-week, double-blind, placebo-controlled, South African Phase IIa trial in 116 patients showed that dimiracetam was well tolerated at doses of up to 1,600 mg twice daily. There were no significant differences between dimiracetam and placebo in the proportion of patients who presented with clinically relevant laboratory worsening (21.7% vs. 19.1%, p=0.73), with worsening CD4+ T cell counts (40.6% vs. 53.2%, p=0.18), with worsening HIV viral load (31.3% vs. 25%, p=0.47), or with worsening of their general clinical condition (2.9% vs. 2.1%, p=1.0). ...